Rothschild Asset Management Inc. Boosts Stake in Ionis Pharmaceuticals Inc (IONS)

Rothschild Asset Management Inc. boosted its stake in Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 8.4% during the first quarter, Holdings Channel reports. The fund owned 240,122 shares of the company’s stock after buying an additional 18,587 shares during the period. Rothschild Asset Management Inc.’s holdings in Ionis Pharmaceuticals were worth $9,653,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the company. Hanseatic Management Services Inc. purchased a new stake in shares of Ionis Pharmaceuticals during the first quarter valued at about $138,000. Westpac Banking Corp purchased a new stake in shares of Ionis Pharmaceuticals during the first quarter valued at about $171,000. Soros Fund Management LLC purchased a new stake in shares of Ionis Pharmaceuticals during the fourth quarter valued at about $206,000. First Allied Advisory Services Inc. purchased a new stake in shares of Ionis Pharmaceuticals during the fourth quarter valued at about $239,000. Finally, Capstone Asset Management Co. increased its stake in shares of Ionis Pharmaceuticals by 10.3% in the first quarter. Capstone Asset Management Co. now owns 5,148 shares of the company’s stock valued at $207,000 after buying an additional 480 shares during the last quarter. 87.76% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Shares of Ionis Pharmaceuticals Inc (NASDAQ IONS) traded up 0.26% during trading on Friday, reaching $50.11. 970,492 shares of the company traded hands. Ionis Pharmaceuticals Inc has a 52 week low of $20.49 and a 52 week high of $57.00. The company’s market capitalization is $6.21 billion. The firm’s 50 day moving average price is $46.34 and its 200-day moving average price is $45.37.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings results on Tuesday, May 9th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.13. The firm had revenue of $110.30 million for the quarter, compared to analysts’ expectations of $86.03 million. Ionis Pharmaceuticals had a negative net margin of 77.30% and a negative return on equity of 120.60%. The firm’s quarterly revenue was up 199.2% on a year-over-year basis. During the same period in the prior year, the company posted ($0.52) earnings per share. Equities analysts anticipate that Ionis Pharmaceuticals Inc will post ($0.39) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Rothschild Asset Management Inc. Boosts Stake in Ionis Pharmaceuticals Inc (IONS)” was first published by Mideast Time and is the property of of Mideast Time. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://www.mideasttime.com/rothschild-asset-management-inc-boosts-stake-in-ionis-pharmaceuticals-inc-ions/1767052.html.

IONS has been the subject of several research analyst reports. Piper Jaffray Companies set a $51.00 price target on shares of Ionis Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, May 10th. Zacks Investment Research raised shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $51.00 price target for the company in a research note on Monday, February 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $64.00 price target on shares of Ionis Pharmaceuticals in a research note on Monday, March 6th. BMO Capital Markets reaffirmed a “buy” rating and set a $59.00 price target on shares of Ionis Pharmaceuticals in a research note on Friday, June 2nd. Finally, Vetr raised shares of Ionis Pharmaceuticals from a “sell” rating to a “hold” rating and set a $37.67 price target for the company in a research note on Tuesday, March 21st. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $43.97.

In related news, SVP Patrick R. O’neil sold 1,000 shares of the company’s stock in a transaction on Wednesday, April 12th. The shares were sold at an average price of $40.07, for a total value of $40,070.00. Following the sale, the senior vice president now directly owns 10,449 shares of the company’s stock, valued at $418,691.43. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Chairman Stanley T. Crooke sold 22,000 shares of the company’s stock in a transaction on Thursday, April 13th. The shares were sold at an average price of $40.69, for a total transaction of $895,180.00. Following the completion of the sale, the chairman now directly owns 48,014 shares in the company, valued at $1,953,689.66. The disclosure for this sale can be found here. Insiders sold 46,220 shares of company stock worth $2,019,538 over the last ninety days. 1.86% of the stock is currently owned by corporate insiders.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:IONS”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals Inc (NASDAQ:IONS).

Receive News & Ratings for Ionis Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.